AlphaGrep UK’s Protagonist Therapeutics PTGX Stock Holding History

AlphaGrep UK’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-3,070	Closed	-$268K	–	905
2025 Q4	$268K	Buy	+3,070	New	+$251K	0.09%	492

Other funds holding PTGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

AlphaGrep UK's PTGX Position: Q1 2026 in Review

AlphaGrep UK sold out of Protagonist Therapeutics (PTGX) in Q1 2026, closing a stake of 3,070 shares — an estimated $268K sold.

AlphaGrep UK first reported a position in PTGX in Q4 2025 and held it in 1 quarter. The position peaked at $268K in Q4 2025. 319 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

AlphaGrep UK reported no remaining Protagonist Therapeutics position as of Q1 2026 after selling out during the quarter.
AlphaGrep UK sold 3,070 Protagonist Therapeutics shares in Q1 2026, an estimated $268K.
AlphaGrep UK first reported a position in Protagonist Therapeutics in Q4 2025 and held it in 1 quarter.
AlphaGrep UK's Protagonist Therapeutics position peaked at $268K in Q4 2025.
319 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on AlphaGrep UK's 13F filing for Q1 2026, filed 13 Aug 2026.